학술논문
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Document Type
article
Author
Uppaluri, Ravindra; Campbell, Katie M; Egloff, Ann Marie; Zolkind, Paul; Skidmore, Zachary L; Nussenbaum, Brian; Paniello, Randal C; Rich, Jason T; Jackson, Ryan; Pipkorn, Patrik; Michel, Loren S; Ley, Jessica; Oppelt, Peter; Dunn, Gavin P; Barnell, Erica K; Spies, Nicholas C; Lin, Tianxiang; Li, Tiantian; Mulder, David T; Hanna, Youstina; Cirlan, Iulia; Pugh, Trevor J; Mudianto, Tenny; Riley, Rachel; Zhou, Liye; Jo, Vickie Y; Stachler, Matthew D; Hanna, Glenn J; Kass, Jason; Haddad, Robert; Schoenfeld, Jonathan D; Gjini, Evisa; Lako, Ana; Thorstad, Wade; Gay, Hiram A; Daly, Mackenzie; Rodig, Scott J; Hagemann, Ian S; Kallogjeri, Dorina; Piccirillo, Jay F; Chernock, Rebecca D; Griffith, Malachi; Griffith, Obi L; Adkins, Douglas R
Source
Clinical Cancer Research. 26(19)
Subject
Language
Abstract
PurposePembrolizumab improved survival in patients with recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). The aims of this study were to determine if pembrolizumab would be safe, result in pathologic tumor response (pTR), and lower the relapse rate in patients with resectable human papillomavirus (HPV)-unrelated HNSCC.Patients and methodsNeoadjuvant pembrolizumab (200 mg) was administered and followed 2 to 3 weeks later by surgical tumor ablation. Postoperative (chemo)radiation was planned. Patients with high-risk pathology (positive margins and/or extranodal extension) received adjuvant pembrolizumab. pTR was quantified as the proportion of the resection bed with tumor necrosis, keratinous debris, and giant cells/histiocytes: pTR-0 (